Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
Borgquist, Signe LU ; Jögi, Annika LU ; Ponten, Fredrik ; Rydén, Lisa LU
; Brennan, Donal J.
and Jirström, Karin
LU
(2008)
In Breast Cancer Research
10(5).
- Abstract
- Introduction We have previously reported that tumour-specific expression of the rate-limiting enzyme, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR), in the mevalonate pathway is associated with more favourable tumour parameters in breast cancer. In the present study, we examined the prognostic value of HMG-CoAR expression in a large cohort of primary breast cancer patients with long-term follow up. Methods The expression of HMG-CoAR was assessed by immunohistochemistry on tissue microarrays with tumour specimens from 498 consecutive cases of breast cancer with a median follow-up of 128 months. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the rate of recurrence-free survival (RFS) and... (More)
- Introduction We have previously reported that tumour-specific expression of the rate-limiting enzyme, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR), in the mevalonate pathway is associated with more favourable tumour parameters in breast cancer. In the present study, we examined the prognostic value of HMG-CoAR expression in a large cohort of primary breast cancer patients with long-term follow up. Methods The expression of HMG-CoAR was assessed by immunohistochemistry on tissue microarrays with tumour specimens from 498 consecutive cases of breast cancer with a median follow-up of 128 months. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the rate of recurrence-free survival (RFS) and breast cancer specific survival (BCSS). Results In line with our previous findings, tumour-specific HMG-CoAR expression was associated with low grade (p < 0.001), small size (p = 0.007), oestrogen receptor (ER) positive (p = 0.01), low Ki-67 (p = 0.02) tumours. Patients with tumours expressing HMG-CoAR had a significantly prolonged RFS, even when adjusted for established prognostic factors (relative risk [RR] = 0.60, 95% confidence interval [CI] 0.40 to 0.92; p = 0.02). In ER-negative tumours, however, there was a trend, that was not significantly significant, towards a shorter RFS in HMG-CoAR expressing tumours. Conclusions HMG-CoAR expression is an independent predictor of a prolonged RFS in primary breast cancer. This may, however, not be true for ER-negative tumours. Further studies are needed to shed light on the value of HMG-CoAR expression as a surrogate marker of response to statin treatment, especially with respect to hormone receptor status. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1305726
- author
- Borgquist, Signe
LU
; Jögi, Annika
LU
; Ponten, Fredrik
; Rydén, Lisa
LU
; Brennan, Donal J.
and Jirström, Karin
LU
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Breast Cancer Research
- volume
- 10
- issue
- 5
- article number
- R79
- publisher
- BioMed Central (BMC)
- external identifiers
-
- wos:000261559000016
- scopus:59449084603
- pmid:18808688
- ISSN
- 1465-5411
- DOI
- 10.1186/bcr2146
- language
- English
- LU publication?
- yes
- id
- 52de5745-9734-4101-aa29-6e160c26e3c0 (old id 1305726)
- date added to LUP
- 2016-04-01 12:03:48
- date last changed
- 2025-10-14 10:21:26
@article{52de5745-9734-4101-aa29-6e160c26e3c0,
abstract = {{Introduction We have previously reported that tumour-specific expression of the rate-limiting enzyme, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR), in the mevalonate pathway is associated with more favourable tumour parameters in breast cancer. In the present study, we examined the prognostic value of HMG-CoAR expression in a large cohort of primary breast cancer patients with long-term follow up. Methods The expression of HMG-CoAR was assessed by immunohistochemistry on tissue microarrays with tumour specimens from 498 consecutive cases of breast cancer with a median follow-up of 128 months. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the rate of recurrence-free survival (RFS) and breast cancer specific survival (BCSS). Results In line with our previous findings, tumour-specific HMG-CoAR expression was associated with low grade (p < 0.001), small size (p = 0.007), oestrogen receptor (ER) positive (p = 0.01), low Ki-67 (p = 0.02) tumours. Patients with tumours expressing HMG-CoAR had a significantly prolonged RFS, even when adjusted for established prognostic factors (relative risk [RR] = 0.60, 95% confidence interval [CI] 0.40 to 0.92; p = 0.02). In ER-negative tumours, however, there was a trend, that was not significantly significant, towards a shorter RFS in HMG-CoAR expressing tumours. Conclusions HMG-CoAR expression is an independent predictor of a prolonged RFS in primary breast cancer. This may, however, not be true for ER-negative tumours. Further studies are needed to shed light on the value of HMG-CoAR expression as a surrogate marker of response to statin treatment, especially with respect to hormone receptor status.}},
author = {{Borgquist, Signe and Jögi, Annika and Ponten, Fredrik and Rydén, Lisa and Brennan, Donal J. and Jirström, Karin}},
issn = {{1465-5411}},
language = {{eng}},
number = {{5}},
publisher = {{BioMed Central (BMC)}},
series = {{Breast Cancer Research}},
title = {{Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer}},
url = {{http://dx.doi.org/10.1186/bcr2146}},
doi = {{10.1186/bcr2146}},
volume = {{10}},
year = {{2008}},
}